News
UNCY
6.23
-4.15%
-0.27
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Reuters · 3d ago
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close
NASDAQ · 4d ago
Weekly Report: what happened at UNCY last week (1124-1128)?
Weekly Report · 5d ago
Unicycive Therapeutics to Participate in Piper Sandler Healthcare Conference
Reuters · 11/25 12:05
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Barchart · 11/25 06:05
Weekly Report: what happened at UNCY last week (1117-1121)?
Weekly Report · 11/24 09:41
Weekly Report: what happened at UNCY last week (1110-1114)?
Weekly Report · 11/17 09:41
Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
TipRanks · 11/15 16:45
Unicycive Therapeutics Doubles Stock Sale Agreement
TipRanks · 11/14 22:34
UNICYCIVE THERAPEUTICS INC - INCREASES ATM OFFERING TO $100 MLN - SEC FILING
Reuters · 11/14 22:12
Unicycive Therapeutics (UNCY) Gets a Buy from Noble Financial
TipRanks · 11/13 14:55
Positive Outlook for Unicycive Therapeutics Amidst Promising Developments and Financial Stability
TipRanks · 11/13 11:45
Unicycive Therapeutics GAAP EPS of -$0.46 beats by $0.07
Seeking Alpha · 11/12 12:55
Unicycive Therapeutics reports Q3 EPS (46c), consensus (53c)
TipRanks · 11/12 12:21
Unicycive Therapeutics sees cash runway into 2027
TipRanks · 11/12 12:21
Unicycive Therapeutics Q3 net loss widens to $6 mln
Reuters · 11/12 12:13
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Strategy
Reuters · 11/12 12:10
*Unicycive Therapeutics: Expected Runway Into 2027 >UNCY
Dow Jones · 11/12 12:07
Unicycive Therapeutics reports Q3 results with $42.7 million cash and plans OLC NDA resubmission by year-end
Reuters · 11/12 12:05
UNICYCIVE THERAPEUTICS INC - ON TRACK TO RESUBMIT NDA FOR OXYLANTHANUM CARBONATE BY YEAR-END
Reuters · 11/12 12:05
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.